Dr. Vivek Subbiah is an Associate Professor in the Department of Investigational Cancer Therapeutics, the Center Clinical Medical Director of the Clinical Center for Targeted Therapy in The University of Texas MD Anderson Cancer Center.
He serves as the Principal Investigator in over 50 Phase I/II trials. His research interests are drug development in rare cancers. He has led several first-in-human and practice changing clinical trials that have led to US FDA approval, EMA approval and approval in multiple geographies e.g. dabrafenib plus trametinib for anaplastic thyroid cancer, vemurafenib for Erdheim-Chester disease, lurbinectedin for small cell lung cancer, selpercatinib and pralsetinib for RET positive non-small cell lung cancer and RET positive thyroid cancer. His trial portfolio includes trials that target BRAF, MEK, RET, CDK, WNT, VEGF, mTOR, EZH2-EED pathways, novel immunotherapy combination trials GITR, TLR7/9, PD1, WT1, several first in human antibody drug conjugates and radiopharmaceuticals.
He has published over 250 peer-reviewed articles in several prestigious journals such as The New England Journal of Medicine, Journal of Clinical Oncology, JAMA Oncology, Cancer Discovery, Lancet Oncology, Nature Reviews Clinical Oncology, Lancet Diabetes and Endocrinology and Clinical Cancer Research.
He is a member of the ESMO Translational Research and Precision Medicine Working Group and Annals of Oncology Editorial Board.